GANX
Gain Therapeutics, Inc. NASDAQ Listed Mar 19, 2021$1.87
Mkt Cap $79.8M
52w Low $1.41
15.7% of range
52w High $4.34
50d MA $2.14
200d MA $2.18
P/E (TTM)
-3.1x
EV/EBITDA
-4.6x
P/B
3.3x
Debt/Equity
0.0x
ROE
-108.6%
P/FCF
-5.7x
RSI (14)
—
ATR (14)
—
Beta
0.11
50d MA
$2.14
200d MA
$2.18
Avg Volume
686.2K
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
CIK (SEC)
Phone
301 500 1556
4800 Montgomery Lane · Bethesda, MD 20814 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.14 | -0.11 | +21.4% | 1.89 | +0.5% | -3.2% | -1.6% | +7.8% | +0.0% | -4.6% | — |
| Nov 12, 2025 | AMC | -0.15 | -0.15 | +0.0% | 2.95 | -0.7% | +1.4% | -5.4% | -0.4% | +1.1% | -3.5% | — |
| Aug 12, 2025 | AMC | -0.17 | -0.19 | -11.8% | 1.53 | -3.3% | +1.3% | -0.6% | +12.3% | +2.3% | -4.5% | — |
| May 14, 2025 | AMC | -0.16 | -0.16 | +0.0% | 1.86 | -0.5% | -2.7% | +11.0% | -2.5% | -2.6% | -5.2% | — |
| Mar 27, 2025 | AMC | -0.18 | -0.11 | +38.9% | 2.07 | -2.4% | -8.7% | +1.1% | -5.2% | +4.4% | -5.3% | — |
| Nov 14, 2024 | AMC | -0.23 | -0.17 | +26.1% | 1.75 | -5.1% | +5.7% | -8.6% | +1.8% | -3.5% | -2.4% | — |
| Aug 8, 2024 | AMC | -0.31 | -0.42 | -35.5% | 0.97 | +1.3% | +1.5% | -4.4% | -0.3% | +19.6% | +9.8% | — |
| May 14, 2024 | AMC | -0.30 | -0.22 | +26.7% | 2.34 | +4.7% | +12.0% | +2.7% | -2.2% | -4.6% | -0.4% | — |
| Mar 26, 2024 | AMC | -0.32 | -0.29 | +9.4% | 3.80 | +1.1% | -1.8% | +1.1% | +1.6% | +1.6% | +2.6% | — |
| Nov 14, 2023 | AMC | -0.47 | -0.37 | +21.3% | 2.78 | -1.5% | +4.3% | -4.8% | -2.2% | +0.7% | -23.9% | — |
| Aug 10, 2023 | AMC | -0.33 | -0.62 | -87.9% | 3.55 | +2.0% | -0.8% | +6.2% | -3.3% | -1.5% | +4.5% | — |
| May 12, 2023 | AMC | -0.40 | -0.43 | -7.5% | 5.17 | +0.2% | -1.7% | -2.6% | +1.6% | -5.0% | +4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.25 | $2.38 | +5.8% | +28.0% | +10.8% | -3.4% | +4.5% | -2.2% |
| Oct 15 | BTIG | Maintains | Buy → Buy | — | $2.04 | $1.98 | -2.9% | -8.3% | -3.2% | +3.3% | +2.7% | +9.4% |
| Oct 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.97 | $2.01 | +2.0% | -3.6% | +7.4% | -8.3% | -3.2% | +3.3% |
| Oct 7 | Maxim Group | Maintains | Buy → Buy | — | $2.22 | $2.29 | +3.2% | -9.0% | +2.5% | +0.5% | -5.3% | -3.6% |
| Sep 8 | BTIG | Maintains | Buy → Buy | — | $1.76 | $1.77 | +0.6% | -0.6% | -2.3% | +1.2% | -0.6% | -3.5% |
| Aug 13 | Roth Capital | Maintains | Buy → Buy | — | $1.53 | $1.48 | -3.3% | +1.3% | -0.6% | +12.3% | +2.3% | -4.5% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.64 | $1.66 | +1.2% | +3.0% | -5.3% | +5.0% | +5.4% | +0.0% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.01 | $1.95 | -3.0% | -2.5% | -2.6% | -5.2% | -0.6% | +0.0% |
| Mar 28 | Chardan Capital | Maintains | Buy → Buy | — | $2.07 | $2.02 | -2.4% | -8.7% | +1.1% | -5.2% | +4.4% | -5.3% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.11 | $2.14 | +1.4% | +13.7% | -0.8% | +3.8% | -7.3% | +2.2% |
| Dec 24 | Roth MKM | Maintains | Buy → Buy | — | $1.57 | $1.59 | +1.3% | +1.3% | +0.6% | +10.0% | +23.9% | -0.9% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.72 | $1.79 | +4.1% | +5.8% | -4.9% | +0.6% | +6.9% | -5.9% |
| Oct 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.98 | $2.08 | +5.1% | +3.0% | -3.4% | +5.1% | +13.5% | +2.1% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.78 | $1.81 | +1.7% | -7.9% | +0.0% | +4.9% | +5.8% | +17.0% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.09 | $1.07 | -1.8% | -4.6% | +0.0% | +4.8% | -3.7% | +10.5% |
| Aug 9 | Chardan Capital | Maintains | Buy → Buy | — | $0.97 | $0.98 | +1.3% | +1.5% | -4.4% | -0.3% | +19.6% | +9.8% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.20 | $1.21 | +0.8% | +13.3% | +1.5% | -9.4% | +4.0% | -2.3% |
| Jul 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.12 | $1.20 | +7.1% | +7.1% | -3.3% | +3.4% | -6.7% | +5.4% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.51 | $2.61 | +4.0% | +1.6% | -3.1% | -0.8% | +2.0% | -6.4% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.42 | $2.45 | +1.2% | -0.4% | -1.2% | +5.5% | +1.6% | -3.1% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.34 | $2.45 | +4.7% | +12.0% | +2.7% | -2.2% | -4.6% | -0.4% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.19 | $3.10 | -2.8% | -3.8% | -1.3% | -1.0% | -2.3% | +1.4% |
| Apr 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.17 | $3.13 | -1.3% | +6.9% | -5.9% | -3.8% | -1.3% | -1.0% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.77 | $4.00 | +6.1% | +1.6% | +1.6% | +2.6% | -10.3% | -0.6% |
| Mar 27 | Chardan Capital | Maintains | Buy → Buy | — | $3.80 | $3.84 | +1.1% | -1.8% | +1.1% | +1.6% | +1.6% | +2.6% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.20 | $2.38 | +8.2% | +6.8% | +2.1% | +3.3% | +1.6% | +7.9% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.70 | $3.61 | -2.4% | -4.3% | -2.0% | -2.0% | -5.0% | +3.4% |
| Aug 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.44 | $3.48 | +1.2% | -3.8% | +1.2% | -0.6% | -1.8% | +11.6% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.52 | $3.57 | +1.4% | +6.2% | -3.3% | -1.5% | +4.5% | -2.4% |
| Aug 14 | Chardan Capital | Maintains | Buy → Buy | — | $3.52 | $3.57 | +1.4% | +6.2% | -3.3% | -1.5% | +4.5% | -2.4% |
| Jun 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.87 | $4.94 | +1.4% | +0.0% | +2.3% | -0.4% | -1.8% | +3.7% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.17 | $5.18 | +0.2% | -1.7% | -2.6% | +1.6% | -5.0% | +4.0% |
| May 15 | Chardan Capital | Maintains | Buy → Buy | — | $5.17 | $5.18 | +0.2% | -1.7% | -2.6% | +1.6% | -5.0% | +4.0% |
| Mar 27 | Chardan Capital | Maintains | Buy → Buy | — | $4.90 | $4.94 | +0.8% | -3.1% | -1.5% | +3.0% | -2.3% | +2.3% |
| Nov 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.09 | $3.08 | -0.3% | +0.3% | -1.6% | -1.0% | +0.7% | +0.7% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.21 | $3.25 | +1.2% | -3.4% | +0.6% | +0.6% | +1.0% | -2.7% |
| Nov 14 | BTIG | Maintains | Buy → Buy | — | $3.21 | $3.25 | +1.2% | -3.4% | +0.6% | +0.6% | +1.0% | -2.7% |
| Aug 19 | B. Riley Securities | Downgrade | Buy → Neutral | — | $3.82 | $3.80 | -0.5% | -4.2% | -11.2% | +4.9% | +0.9% | +2.3% |
| Mar 29 | B. Riley Securities | Maintains | Buy → Buy | — | $3.96 | $4.16 | +5.1% | +3.8% | -0.5% | +0.0% | +4.4% | +6.8% |
No insider trades available.
8-K
Unknown — 8-K Filing
GANX's lead candidate GT-02287 advanced clinically in 2025, but as a pre-revenue biotech, investors should monitor upcoming trial data and cash runway closely to assess viability.
Mar 26
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Genentech's advancement of GT-02287 into Phase 1b trials for Parkinson's disease validates its GCase modulator platform, potentially opening a significant neurology market opportunity that could drive future revenue growth and stock appreciation.
Mar 18
8-K · 7.01
! Medium
Gain Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Gain Therapeutics disclosed material non-public information on February 3, 2026, requiring simultaneous public dissemination to ensure fair investor access under Regulation FD rules.
Feb 3
Data updated apr 25, 2026 10:41am
· Source: massive.com